Evidence map›Paper›PMID 41923154›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy.

Atsushi Shimizu, Yu Iwabuchi, Shogyoku Bun, Memi Watanabe, Masahito Kubota, Sho Shimohama, Toshiki Tezuka, Keisuke Takahata, Hajime Tabuchi, Morinobu Seki and 15 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Atsushi ShimizuDepartment of Radiology, Keio University School of Medicine, Tokyo, Japan.ORCID 0009-0008-8968-044X
Yu IwabuchiDepartment of Radiology, Keio University School of Medicine, Tokyo, Japan.
Shogyoku BunDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Memi WatanabeDepartment of Radiology, Keio University School of Medicine, Tokyo, Japan.
Masahito KubotaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Sho ShimohamaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Toshiki TezukaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Keisuke TakahataDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Hajime TabuchiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Morinobu SekiDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Yuki MomotaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Yasuharu YamamotoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Ryo ShikimotoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Yu MimuraDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Shin KuroseDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Ryosuke SakuraiDepartment of Radiology, Keio University School of Medicine, Tokyo, Japan.
Toshiki TakayamaDepartment of Psychiatry and Behavioral Science, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Yuka HoshinoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Takayuki HoshinoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Natsumi SuzukiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Ayaka MorimotoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Azusa OsumiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Masaru MimuraDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Masahiro JinzakiDepartment of Radiology, Keio University School of Medicine, Tokyo, Japan.
Daisuke ItoDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.

Funding

AMED to EISAI Co., Ltd 17pc0101006Japan Agency for Medical Research and Development JP17pc0101006Japan Society for the Promotion of Science 16H06277
6 · The paper itself

Abstract

introductionFlorzolotau (18F) positron emission tomography visualizes three- and four-repeat tau isoforms. We aimed to evaluate correlation of tau tracer retention with neuropsychological performance across the Alzheimer's disease (AD) continuum and non-AD tauopathies.

methodsThis study enrolled 178 patients with cognitive impairment and 60 volunteers. Participants were divided into AD continuum (n = 120) and non-AD tauopathy (n = 98) groups and assessed using the Mini-Mental State Examination (MMSE), Clinical Dementia Rating, Functional Activity Questionnaire, Wechsler Memory Scale-Revised Logical Memory, Alzheimer's Disease Assessment Scale Cognitive subscale, Trail Making Test (TMT), word fluency, and the Japanese Adult Reading Test. Voxel-based analysis was performed.

resultsIn the AD continuum group, all cognitive test performances significantly correlated with tracer uptake, particularly in the left cortical areas. In the non-AD tauopathy group, strong correlations were observed with MMSE and TMT Part B performance. DISCUSSION: Neuropsychological performance and regional tau pathology distribution are correlated in patients with tauopathy, with differences between AD continuum and non-AD tauopathy. CLINICAL

trial registrationThis trial is registered with UMIN Clinical Trials (UMIN-CTR number: 000032027); submitted for registration on March 30, 2018; first patient enrolment was on July 3, 2018.

Indexed as

Alzheimer DiseaseCarbolinesCognitive DysfunctionTauopathiesAgedAged, 80 and overBrainFemaleHumansMaleMiddle AgedNeuropsychological TestsPositron-Emission Tomographytau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinestau Proteinsfrontotemporal lobar degenerationneuropsychological testStatistical Parametric Mappingtau positron emission tomography

Identifiers

PMID41923154
PMCPMC13045494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.